The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites--a randomized multicentric study
- PMID: 18251131
The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites--a randomized multicentric study
Abstract
Background/aims: Postparacentesis circulatory dysfunction is the most severe complication of ascites paracentesis. The aim of our study was to compare the standard treatment with the administration of a vasoconstrictor terlipressin.
Methodology: Forty-nine patients treated by paracentesis due to tense ascites were randomized for the treatment with albumin (8g/L of removed ascites) or terlipressin (1 mg every four hours for 48 hours). The blood pressure, heart rate, diuresis, electrocardiograph, standard biochemical and hematological parameters, sodium, potassium and nitrogen urinary excretion, aldosterone and renin activity in the blood plasma were monitored for a period of 72 hours.
Results: In any parameter of hemodynamic changes, no statistically significant difference was demonstrated between randomized groups, in particular measurements as well as in the development in the course of the first three days after the intervention. The result suggests similar efficacy of the circulatory dysfunction prevention after the paracentesis in both treatment procedures. In both groups, on the first three days, there was a tendency to improve hemodynamics reflected by the renin-angiotensin-aldosteron system activity. In the terlipressin group, this tendency approached statistically significant levels.
Conclusions: The administration of terlipressin in a dose of 1 mg every fourth hour performed for a period of 48 hours was as effective as intravenous albumin in preventing hemodynamic changes in patients with tense ascites treated by paracentesis. The treatment was well tolerated.
Similar articles
-
Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):303-7. doi: 10.1111/j.1440-1746.2006.04182.x. J Gastroenterol Hepatol. 2006. PMID: 16460491 Clinical Trial.
-
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.Liver Int. 2008 Aug;28(7):1019-25. doi: 10.1111/j.1478-3231.2008.01734.x. Epub 2008 Apr 11. Liver Int. 2008. PMID: 18410283 Clinical Trial.
-
Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites.Hepatology. 2003 May;37(5):1147-53. doi: 10.1053/jhep.2003.50169. Hepatology. 2003. PMID: 12717396 Clinical Trial.
-
Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence.Can J Gastroenterol Hepatol. 2020 Jun 22;2020:5106958. doi: 10.1155/2020/5106958. eCollection 2020. Can J Gastroenterol Hepatol. 2020. PMID: 32676484 Free PMC article.
-
The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.Hepatology. 2006 Mar;43(3):385-94. doi: 10.1002/hep.21094. Hepatology. 2006. PMID: 16496352 Review.
Cited by
-
Revision and update on clinical practice guideline for liver cirrhosis.Korean J Hepatol. 2012 Mar;18(1):1-21. doi: 10.3350/kjhep.2012.18.1.1. Epub 2012 Mar 22. Korean J Hepatol. 2012. PMID: 22511898 Free PMC article. No abstract available.
-
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.Cochrane Database Syst Rev. 2020 Jan 16;1(1):CD013123. doi: 10.1002/14651858.CD013123.pub2. Cochrane Database Syst Rev. 2020. PMID: 31978257 Free PMC article.
-
The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction.Clin Mol Hepatol. 2015 Dec;21(4):365-71. doi: 10.3350/cmh.2015.21.4.365. Epub 2015 Dec 24. Clin Mol Hepatol. 2015. PMID: 26770925 Free PMC article.
-
KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.Clin Mol Hepatol. 2018 Sep;24(3):230-277. doi: 10.3350/cmh.2018.1005. Epub 2018 Jul 9. Clin Mol Hepatol. 2018. PMID: 29991196 Free PMC article. Review. No abstract available.
-
Evaluation and management of patients with refractory ascites.World J Gastroenterol. 2009 Jan 7;15(1):67-80. doi: 10.3748/wjg.15.67. World J Gastroenterol. 2009. PMID: 19115470 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical